FDA confirmed CMC and device plans are Phase 3 ready, coinciding with strengthening of US and EU patent estates.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA confirmed CMC and device plans are Phase 3 ready, coinciding with strengthening of US and EU patent estates.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
European Patent Office
one of the two organs of the European Patent Organisation
Nothing else this week.
Related events
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- MDR/IVDR reforms require adoption by the European Parliament, referencing US FDA pre-submission meetings.
- CStone Pharmaceuticals is seeking consensus on a global Phase III protocol for Pralsetinib, while sales increased by 500% year-over-year.
- FDA approval enables commercial opportunity involving CBRE Group.
- Congress considered proposals to strengthen FDA authority regarding medical device regulation and minimum standards.